Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2280 • ACR Convergence 2023
The LFA-REAL Clinician Reported Outcome Predicts Damage in Patients with Systemic Lupus Erythematosus (SLE). Data from a Prevalent Latin American Lupus Cohort
Manuel Ugarte-Gil¹, Rocío Gamboa-Cárdenas², Victor Pimentel-Quiroz², Cristina Reategui-Sokolova³, Claudia Elera-Fitzcarrald⁴, Erika Noriega⁵, Cesar Pastor-Asurza⁶, Zoila Rodriguez-Bellido⁶, Risto Perich-Campos⁶ and Graciela S Alarcón⁷, ¹Universidad Cientifica del Sur, Lima, Peru, ²Universidad Cientifica del Sur/Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, ³Hospital Guillermo Almenara Irigoyen, EsSalud/Universidad San Ignacio de Loyola, Lima, Peru, ⁴Hospital Guillermo Almenara Irigoyen, EsSalud/Universidad Privada San Juan Bautista, Lima, Peru, ⁵Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, ⁶Hospital Guillermo Almenara Irigoyen, EsSalud/Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁷Heersink School of Medicine. The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) clinican-reported outcome (ClinRO) correlates well with other disease activity indices such us…
Abstract Number: 2297 • ACR Convergence 2023
Interferon-α as a Biomarker to Predict Flares in Lupus Nephritis
Laura Patricia Whittall Garcia¹, Dafna Gladman², Murray Urowitz³, Zahi Touma⁴ and Joan Wither¹, ¹University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Type I Interferons (IFN-I) play a role in SLE and Lupus Nephritis (LN) pathogenesis. We have recently shown that IFN-I gene expression predicts the…
Abstract Number: 2313 • ACR Convergence 2023
Utilization of Palliative Care in Hospitalized Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Analysis
Saman Tanveer¹, Hema Pinnam², Fatima Tanveer³ and Daksh Ahluwalia¹, ¹John H. Stroger Jr. Hospital of Cook County, Chicago, IL, ²J.S.S. Medical College, Mysore, India, ³CMH Lahore Medical College, Lahore, Pakistan
Background/Purpose: We aimed to investigate trends in utilization of hospital palliative care services among hospitalized patients with systemic lupus erythematosus (SLE) and analyze its impact…
Abstract Number: 2330 • ACR Convergence 2023
Disease-Related Outcomes of Cognitive Behavioral Therapy in Randomized Control Trial for Youth with Childhood-onset SLE: A Secondary Analysis
Natoshia Cunningham¹, Michelle Adler¹, Ashley Danguecan², Mallet Reid¹, Samantha Ely³, Mathew Reeves⁴, Lawrence Ng², Paris Moaf², Tala El Tal⁵, Sarah Mossad², Luana Flores Pereira², Deborah Levy², Linda Hiraki², Jennifer Stinson², Sara Ahola Kohut², khalid abulaban⁶, Elizabeth Kessler⁷, Stacy Allen⁸, Tamar Rubinstein⁹, Evin Rothschild¹⁰, Natalie Rosenwasser¹¹, Kabita Nanda¹², Susan Canny¹³, Emily Smitherman¹⁴, Livie Huie¹⁵, James Birmingham¹⁶, Ekemini Ogbu¹⁷, Hermine Brunner¹⁸, Dhriti Sharma¹⁹, Allison Thompson²⁰, Janel Thompson²¹, Miranda Moyer²⁰, Emily Nguyen²⁰, Angela Chapson²⁰ and Andrea Knight², ¹Michigan State University, Grand Rapids, MI, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Michigan State University, Wayne State University, Grand Rapids, MI, ⁴Michigan State University, East Lansing, MI, ⁵Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, ⁶Helen DeVos Children's Hospital, Ada, MI, ⁷Spectrum Health, Grand Rapids, MI, ⁸Helen DeVos Children's Hospital, Caledonia, MI, ⁹Albert Einstein College of Medicine, Children's Hospital at Montefiore, White Plains, NY, ¹⁰Albert Einstein Medical Center, Children's Hospital at Montefiore, Bronx, NY, ¹¹Seattle Children's Hospital, Seattle, WA, ¹²Seattle Children's Hospital/University of Washington, Seattle, WA, ¹³Seattle Children's Hospital/University of Washington, Seattle, WA, ¹⁴University of Alabama at Birmingham, Birmingham, AL, ¹⁵University of Alabama at Birmingham, Gardendale, AL, ¹⁶Self, Ada, MI, ¹⁷Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Johns Hopkins University, Cincinnati, OH, ¹⁸Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ¹⁹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²⁰Patient Co-Investigative Team, n/a, ²¹Patient Co-Investigative Team, Revere, PA
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is associated with symptoms such as fatigue, pain, and depressive symptoms that contribute to poor health-related quality of life.…
Abstract Number: 2349 • ACR Convergence 2023
Selection of the Dose for Subcutaneous Administration to Non-Japanese Subjects and Intravenous Administration to Japanese Subjects in the First-in-Human Study of DS-7011a, an Anti-TLR7 Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
Li Zhang¹, Jun Tanaka², Michael Dodds³, Mirjam Trame³, Sophia Xu¹, Masafumi Kumazaki⁴, Yoshiaki Tomimori⁵, Samarth Patel¹, Aparna Mohan¹, Giorgio Senaldi¹ and Tarek Leil¹, ¹Daiichi Sankyo, Basking Ridge, NJ, ²Daiichi Sankyo, Inc., Basking Ridge, NJ, ³Certara Strategic Consulting, Princeton, NJ, ⁴Daiichi Sankyo, Tokyo, Japan, ⁵Daiichi Sankyo Co., Ltd., Shinagawa-ku, Japan
Background/Purpose: Toll-like receptor (TLR)7 is a pattern recognition receptor whose ligands include nucleic acids and whose gain-of-function mutations have been reported to result insystemic lupus…
Abstract Number: 2486 • ACR Convergence 2023
Should SLE Patients Entering Clinical Trials Be Required to Have at Least One BILAG a And/or Two BILAG B Scores?
Ewa Olech¹ and Joan Merrill², ¹IQVIA, Rheumatology Consultants, PLLC, Las Vegas, NV, ²Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: High placebo response rates have challenged interpretation of clinical trial results in SLE and may have contributed to failure of some effective treatments. One…
Abstract Number: 2555 • ACR Convergence 2023
Cluster Analysis Reveals Subgroups in Patients with Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Implication for Long-term Prognosis Prediction
YuFang Ding¹, Qian Wang¹, Xinping Tian², Mengtao Li², xiaofeng Zeng¹ and Jiuliang zhao², ¹Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Serologically active clinically quiescent (SACQ) is a clinical state of systemic lupus erythematosus (SLE) characterized by high levels of serologic markers without clinical activity.…
Abstract Number: 0122 • ACR Convergence 2023
Depression, Anxiety and Post-Traumatic Stress Disorder in Association with Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis in the All of Us Research Program
Jeong Yee¹, Emily G. Oakes¹, May Choi², Candace Feldman¹, Elizabeth Karlson¹ and Karen Costenbader³, ¹Brigham and Women's Hospital, Boston, MA, ²University of Calgary, Calgary, AB, Canada, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Cardiovascular disease (CVD) risk is increased for patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Mental health conditions such as depression, anxiety,…
Abstract Number: 0187 • ACR Convergence 2023
Advancing Health Equity with Lupus Stakeholders to Close Care Gaps and Disparities
Shalvi Parikh¹, Monica Messina¹, Shivani Garg¹, Sancia Ferguson², Edmond Ramly³, Andrea Gilmore-Bykovskyi⁴, Katrina Phelps⁵ and Christie M. Bartels⁶, ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, Madison, WI, ³Department of Family Medicine and Community Health, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵School of Nursing, University of Wisconsin-Madison, Madison, WI, ⁶University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: Systemic lupus erythematosus (SLE) care and outcomes are associated with significant racial and socioeconomic disparities in the US, particularly among young Black and Hispanic/Latina…
Abstract Number: 0475 • ACR Convergence 2023
Prevalence of Endometriosis and Polycystic Ovarian Syndrome in Patients with Rheumatic Diseases in the United States
Sabahat Usmani¹, Catherine Lavallee², Maria Antonelli³ and Cuoghi Edens⁴, ¹Weiss Memorial Hospital, Chicago, IL, ²Virginia Tech Carilion School of Medicine, Roanoke, VA, ³MetroHealth System, Cleveland, OH, ⁴University of Chicago, Chicago, IL
Background/Purpose: Endometriosis (ENDO) and Polycystic Ovarian Syndrome (PCOS) are underdiagnosed, often debilitating conditions with unknown etiologies that, like rheumatic diseases, affect reproductive-aged women. Recent studies…
Abstract Number: 0558 • ACR Convergence 2023
Elevated Serum Levels of S100A8/A9 Discriminate Systemic Lupus Erythematosus Patients with Cognitive Impairment from Patients Without Impairment
Carolina Munoz-Grajales¹, Michelle Barraclough², Juan Pablo Diaz Martinez³, Jiandong Su², Kathleen Bingham², Mahta Kakvan⁴, Roberta Kretzmann⁵, Carmela Tartaglia⁶, Lesley Ruttan⁷, May Choi⁸, Simone Appenzeller⁹, Sherief Marzouk⁵, Dennisse Bonilla², Patti Katz¹⁰, Dorcas Beaton¹¹, Robin Green⁵, Joan Wither² and Zahi Touma⁵, ¹UHN/TWH, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶Krembil Brain Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ⁷University Health Network, Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹UNICAMP, Campinas, Brazil, ¹⁰University of California San Francisco, San Rafael, CA, ¹¹Institute for Work & Health, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is one of the most common manifestations of Neuropsychiatric Systemic Lupus Erythematosus (NPSLE). Studies have reported that SLE patients with different…
Abstract Number: 0574 • ACR Convergence 2023
Type I IFN-associated Regulation of Immune Checkpoint Genes in Patients with SLE
Kanwal Zahid Siddiqi¹, Amanda Hempel Zinglersen², Katrine Kjær Iversen¹ and Søren Jacobsen², ¹Copenhagen Research Center for Autoimmune Connective Tissue Diseases (COPEACT), Department of Rheumatology 4242, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark, ²Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Aberrant activation of type I IFN, and subsequent adverse clinical implications, have been widely discussed in relation to SLE. With the lack of consistent…
Abstract Number: 0592 • ACR Convergence 2023
Real-World Treatment Patterns in Patients with Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS)
Martin Aringer¹, Laurent Arnaud², Richard A. Furie³, Eric Morand⁴, Christine Peschken⁵, Barnabas Desta⁶, Eleni Rapsomaniki⁷, Jonatan Hedberg⁸, Tina Grünfeld Eén⁸, Alessandro Sorrentino⁹, Canna Ghia⁹, Stephanie Chen¹⁰ and Bo Ding⁸, ¹Faculty of Medicine TU Dresden, Dresden, Germany, ²University Hospitals of Strasbourg, Strasbourg, France, ³Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁴Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁷BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ⁸BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, ⁹Medical Affairs, AstraZeneca, Cambridge, United Kingdom, ¹⁰BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: The international SLE Prospective Observational Cohort Study (SPOCS) collected data on patients with moderate to severe SLE disease activity from June 2017 through November…
Abstract Number: 0731 • ACR Convergence 2023
ZEB2 Acts as a Crucial Transcriptional Regulator Governing Age-Associated B Cell Formation and Pathogenicity in Systemic Lupus Erythematosus
Dai Dai¹, Shuangshuang Gu¹, Xiaxia Han¹, Huihua Ding², Yang Jiang¹, Sheng Chen¹ and Nan Shen², ¹Shanghai Institute of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), Shanghai, China, ²Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: Age-associated B cells (ABCs) accumulate and contribute to the pathogenesis of systemic autoimmune diseases like lupus. Despite recent insights into the ontogeny and function…
Abstract Number: 0850 • ACR Convergence 2023
Persistence of Urinary Biomarkers of Intrarenal Inflammation Precedes Loss of Kidney Function in Lupus Nephritis
Andrea Fava¹, Mohamed G. Atta¹, Jose Monroy-Trujillo², Derek Fine², Daniel Goldman³, Izmirly peter⁴, H Michael Belmont⁵, the Accelerating Medicines Partnership in RA/SLE⁶, Jill Buyon⁷ and Michelle Petri³, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins School of Medicine, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴NYU, New York, NY, ⁵NYU School of Medicine, New York, NY, ⁶Multiple, Multiple, ⁷NYU Grossman School of Medicine, New York, NY
Background/Purpose: One third of lupus nephritis (LN) patients develop irreversible kidney damage despite achieving a clinical response based on resolution of proteinuria. Furthermore, per protocol…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].